DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge

References

• (CDC) CfDCaP. Botulism. National Center for Emerging and Zoonotic Infectious Diseases Atlanta, GA: CDC.gov, 2014
   Google Scholar
• Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001; 285:1059-70; PMID:11209178; http://dx.doi.org/10.1001/jama.285.8.1059
   PubMed Web of Science ®Google Scholar
• Hanson D. Botulinum toxin: a bioterrorism weapon. Emerg Med Serv. 2004 Apr; 33(4):55-9
   PubMedGoogle Scholar
• Smith LA. Botulism and vaccines for its prevention. Vaccine 2009; 27 Suppl 4:D33-9; PMID:19837283; http://dx.doi.org/10.1016/j.vaccine.2009.08.059
   PubMed Web of Science ®Google Scholar
• Barash JR, Arnon SS. A novel strain of clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 2013; 209:183-91; PMID:24106296; http://dx.doi.org/10.1093/infdis/jit449
   PubMed Web of Science ®Google Scholar
• Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev 1980; 44:419-48; PMID:6252433
   PubMedGoogle Scholar
• Prevention CfDCa. Handbook for epidemiologists, clinicians, and laboratory workers Atlanta, GA: US. Department of Health and Human Services, Public Health Service, 1998; Available at: http://www.cdc.gov/ncidod/dbmd/diseaseinfo/files/botulism.pdf
   Google Scholar
• Rainey GJ, Young JA. Antitoxins: novel strategies to target agents of bioterrorism. Nat Rev Microbiol 2004; 2:721-6; PMID:15372082; http://dx.doi.org/10.1038/nrmicro977
   PubMed Web of Science ®Google Scholar
• Brunger AT, Breidenbach MA, Jin R, Fischer A, Santos JS, Montal M. Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog 2007; 3:1191-4; PMID:17907800; http://dx.doi.org/10.1371/journal.ppat.0030113
   PubMed Web of Science ®Google Scholar
• Koriazova LK, Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 2003; 10:13-8; PMID:12459720; http://dx.doi.org/10.1038/nsb879
   PubMedGoogle Scholar
• Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 2002; 99:11346-50; PMID:12177434; http://dx.doi.org/10.1073/pnas.172229899
   PubMed Web of Science ®Google Scholar
• Shukla HD, Sharma SK. Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol 2005; 31:11-8; PMID:15839401; http://dx.doi.org/10.1080/10408410590912952
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves first botulism antitoxin for use in neutralizing all seven known botulinum nerve serotypes silver spring, MD: US. Food and Drug Administration, 2013
   Google Scholar
• Siegel LS. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol 1988; 26:2351-6; PMID:3235662
   PubMed Web of Science ®Google Scholar
• Dhama K, Mahendran M, Gupta PK, Rai A. DNA vaccines and their applications in veterinary practice: current perspectives. Vet Res Commun 2008; 32:341-56; PMID:18425596; http://dx.doi.org/10.1007/s11259-008-9040-3
   PubMed Web of Science ®Google Scholar
• Mahon BP, Moore A, Johnson PA, Mills KH. Approaches to new vaccines. Crit Rev Biotechnol 1998; 18:257-82; PMID:9887505; http://dx.doi.org/10.1080/0738-859891224167
   PubMed Web of Science ®Google Scholar
• Morrow MP, Weiner DB. DNA drugs come of age. Sci Am 303:48-53; PMID:20583666; http://dx.doi.org/10.1038/scientificamerican0710-48
   PubMed Web of Science ®Google Scholar
• Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med, 2012; 4:155ra138.
   PubMed Web of Science ®Google Scholar
• Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun 1997; 65:3743-52; PMID:9284147
   PubMed Web of Science ®Google Scholar
• Clayton MA, Clayton JM, Brown DR, Middlebrook JL. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 1995; 63:2738-42; PMID:7790092
   PubMed Web of Science ®Google Scholar
• Pless DD, Torres ER, Reinke EK, Bavari S. High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect Immun 2001; 69:570-4; PMID:11119555; http://dx.doi.org/10.1128/IAI.69.1.570-574.2001
   PubMed Web of Science ®Google Scholar
• Tavallaie M, Chenal A, Gillet D, Pereira Y, Manich M, Gibert M, Raffestin S, Popoff MR, Marvaud JC. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett 2004; 572:299-306; PMID:15304366; http://dx.doi.org/10.1016/j.febslet.2004.06.094
   PubMed Web of Science ®Google Scholar
• Trollet C, Pereira Y, Burgain A, Litzler E, Mezrahi M, Seguin J, Manich M, Popoff MR, Scherman D, Bigey P. Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer. Infect Immun 2009; 77:2221-9; PMID:19237523; http://dx.doi.org/10.1128/IAI.01269-08
   PubMed Web of Science ®Google Scholar
• CDC. Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR Morb Mortal Wkly Rep 2011; 60:1454-5.
   PubMedGoogle Scholar
• Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, Frenzel A, Schirrmann T, Thullier P, Sesardic D, et al. Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. MAbs 2014; 6:446-59; PMID:24492304; http://dx.doi.org/10.4161/mabs.27773
   PubMed Web of Science ®Google Scholar
• Shearer JD, Manetz TS, House RV. Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B). Vaccine 2012; 30:1917-26; PMID:22269871; http://dx.doi.org/10.1016/j.vaccine.2012.01.035
   PubMed Web of Science ®Google Scholar
• Pier CL, Tepp WH, Bradshaw M, Johnson EA, Barbieri JT, Baldwin MR. Recombinant holotoxoid vaccine against botulism. Infect Immun 2008; 76:437-42; PMID:17967862; http://dx.doi.org/10.1128/IAI.00843-07
   PubMed Web of Science ®Google Scholar
• Kobayashi R, Kohda T, Kataoka K, Ihara H, Kozaki S, Pascual DW, Staats HF, Kiyono H, McGhee JR, Fujihashi K. A novel neurotoxoid vaccine prevents mucosal botulism. J Immunol 2005; 174:2190-5; PMID:15699151; http://dx.doi.org/10.4049/jimmunol.174.4.2190
   PubMed Web of Science ®Google Scholar
• Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M, Gong Y, Simpson LL. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 2007; 75:3043-54; PMID:17371853; http://dx.doi.org/10.1128/IAI.01893-06
   PubMed Web of Science ®Google Scholar
• Zichel R, Mimran A, Keren A, Barnea A, Steinberger-Levy I, Marcus D, Turgeman A, Reuveny S. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system. Clin Vaccine Immunol 2010; 17:784-92; PMID:20357058; http://dx.doi.org/10.1128/CVI.00496-09
   PubMed Web of Science ®Google Scholar
• Yu YZ, Liu S, Ma Y, Gong ZW, Wang S, Sun ZW. Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors. Hum Vaccin Immunother 2014; 10:1874-9; PMID:25424795; http://dx.doi.org/10.4161/hv.28937
   PubMed Web of Science ®Google Scholar
• Ferreira JL, Maslanka S, Johnson E, Goodnough M. Detection of botulinal neurotoxins A, B, E, and F by amplified enzyme-linked immunosorbent assay: collaborative study. J AOAC Int 2003; 86:314-31; PMID:12723917
   PubMed Web of Science ®Google Scholar
• Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998; 221:35-41; PMID:9894896; http://dx.doi.org/10.1016/S0022-1759(98)00170-7
   PubMed Web of Science ®Google Scholar
• Villarreal D, Wise MC, Walters JN, Reuschel E, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 2014; 74(6):1789-800; PMID:24448242
   PubMed Web of Science ®Google Scholar